Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 85

1.

Tau oligomers mediate α-synuclein toxicity and can be targeted by immunotherapy.

Gerson JE, Farmer KM, Henson N, Castillo-Carranza DL, Carretero Murillo M, Sengupta U, Barrett A, Kayed R.

Mol Neurodegener. 2018 Mar 15;13(1):13. doi: 10.1186/s13024-018-0245-9.

2.

Prospects for strain-specific immunotherapy in Alzheimer's disease and tauopathies.

Bittar A, Sengupta U, Kayed R.

NPJ Vaccines. 2018 Feb 27;3:9. doi: 10.1038/s41541-018-0046-8. eCollection 2018. Review.

3.

The role of microbial amyloid in neurodegeneration.

Friedland RP, Chapman MR.

PLoS Pathog. 2017 Dec 21;13(12):e1006654. doi: 10.1371/journal.ppat.1006654. eCollection 2017 Dec. Review.

4.

Discovery and characterization of stable and toxic Tau/phospholipid oligomeric complexes.

Ait-Bouziad N, Lv G, Mahul-Mellier AL, Xiao S, Zorludemir G, Eliezer D, Walz T, Lashuel HA.

Nat Commun. 2017 Nov 22;8(1):1678. doi: 10.1038/s41467-017-01575-4.

5.

Lysine-Directed Post-translational Modifications of Tau Protein in Alzheimer's Disease and Related Tauopathies.

Kontaxi C, Piccardo P, Gill AC.

Front Mol Biosci. 2017 Aug 11;4:56. doi: 10.3389/fmolb.2017.00056. eCollection 2017. Review.

6.

LTP and memory impairment caused by extracellular Aβ and Tau oligomers is APP-dependent.

Puzzo D, Piacentini R, Fá M, Gulisano W, Li Puma DD, Staniszewski A, Zhang H, Tropea MR, Cocco S, Palmeri A, Fraser P, D'Adamio L, Grassi C, Arancio O.

Elife. 2017 Jul 11;6. pii: e26991. doi: 10.7554/eLife.26991.

7.

Cerebral Microvascular Accumulation of Tau Oligomers in Alzheimer's Disease and Related Tauopathies.

Castillo-Carranza DL, Nilson AN, Van Skike CE, Jahrling JB, Patel K, Garach P, Gerson JE, Sengupta U, Abisambra J, Nelson P, Troncoso J, Ungvari Z, Galvan V, Kayed R.

Aging Dis. 2017 May 2;8(3):257-266. doi: 10.14336/AD.2017.0112. eCollection 2017 May.

8.

Endoplasmic reticulum stress and inflammation in the central nervous system.

Sprenkle NT, Sims SG, Sánchez CL, Meares GP.

Mol Neurodegener. 2017 May 25;12(1):42. doi: 10.1186/s13024-017-0183-y. Review.

9.

Extracellular Tau Oligomers Induce Invasion of Endogenous Tau into the Somatodendritic Compartment and Axonal Transport Dysfunction.

Swanson E, Breckenridge L, McMahon L, Som S, McConnell I, Bloom GS.

J Alzheimers Dis. 2017;58(3):803-820. doi: 10.3233/JAD-170168.

10.

Humanized monoclonal antibody armanezumab specific to N-terminus of pathological tau: characterization and therapeutic potency.

Agadjanyan MG, Zagorski K, Petrushina I, Davtyan H, Kazarian K, Antonenko M, Davis J, Bon C, Blurton-Jones M, Cribbs DH, Ghochikyan A.

Mol Neurodegener. 2017 May 5;12(1):33. doi: 10.1186/s13024-017-0172-1.

11.

Tau oligomers in cerebrospinal fluid in Alzheimer's disease.

Sengupta U, Portelius E, Hansson O, Farmer K, Castillo-Carranza D, Woltjer R, Zetterberg H, Galasko D, Blennow K, Kayed R.

Ann Clin Transl Neurol. 2017 Mar 1;4(4):226-235. doi: 10.1002/acn3.382. eCollection 2017 Apr.

12.

Tau interactome mapping based identification of Otub1 as Tau deubiquitinase involved in accumulation of pathological Tau forms in vitro and in vivo.

Wang P, Joberty G, Buist A, Vanoosthuyse A, Stancu IC, Vasconcelos B, Pierrot N, Faelth-Savitski M, Kienlen-Campard P, Octave JN, Bantscheff M, Drewes G, Moechars D, Dewachter I.

Acta Neuropathol. 2017 May;133(5):731-749. doi: 10.1007/s00401-016-1663-9. Epub 2017 Jan 12.

13.

The Role of the Carboxyl-Terminal Sequence of Tau and MAP2 in the Pathogenesis of Dementia.

Xie C, Miyasaka T.

Front Mol Neurosci. 2016 Dec 27;9:158. doi: 10.3389/fnmol.2016.00158. eCollection 2016. Review.

14.

TRIM28 regulates the nuclear accumulation and toxicity of both alpha-synuclein and tau.

Rousseaux MW, de Haro M, Lasagna-Reeves CA, De Maio A, Park J, Jafar-Nejad P, Al-Ramahi I, Sharma A, See L, Lu N, Vilanova-Velez L, Klisch TJ, Westbrook TF, Troncoso JC, Botas J, Zoghbi HY.

Elife. 2016 Oct 25;5. pii: e19809. doi: 10.7554/eLife.19809.

15.

Soluble pre-fibrillar tau and β-amyloid species emerge in early human Alzheimer's disease and track disease progression and cognitive decline.

Koss DJ, Jones G, Cranston A, Gardner H, Kanaan NM, Platt B.

Acta Neuropathol. 2016 Dec;132(6):875-895. Epub 2016 Oct 21.

16.

Tau Oligomers Associate with Inflammation in the Brain and Retina of Tauopathy Mice and in Neurodegenerative Diseases.

Nilson AN, English KC, Gerson JE, Barton Whittle T, Nicolas Crain C, Xue J, Sengupta U, Castillo-Carranza DL, Zhang W, Gupta P, Kayed R.

J Alzheimers Dis. 2017;55(3):1083-1099.

17.

Potential mechanisms and implications for the formation of tau oligomeric strains.

Gerson JE, Mudher A, Kayed R.

Crit Rev Biochem Mol Biol. 2016 Nov/Dec;51(6):482-496. doi: 10.1080/10409238.2016.1226251. Epub 2016 Sep 21. Review.

18.

Analysis of isoform-specific tau aggregates suggests a common toxic mechanism involving similar pathological conformations and axonal transport inhibition.

Cox K, Combs B, Abdelmesih B, Morfini G, Brady ST, Kanaan NM.

Neurobiol Aging. 2016 Nov;47:113-126. doi: 10.1016/j.neurobiolaging.2016.07.015. Epub 2016 Jul 29.

19.

The Neurotoxic TAU45-230 Fragment Accumulates in Upper and Lower Motor Neurons in Amyotrophic Lateral Sclerosis Subjects.

Vintilescu CR, Afreen S, Rubino AE, Ferreira A.

Mol Med. 2016 Aug 3;22. doi: 10.2119/molmed.2016.00095. [Epub ahead of print]

20.

Extracellular Tau Oligomers Produce An Immediate Impairment of LTP and Memory.

Fá M, Puzzo D, Piacentini R, Staniszewski A, Zhang H, Baltrons MA, Li Puma DD, Chatterjee I, Li J, Saeed F, Berman HL, Ripoli C, Gulisano W, Gonzalez J, Tian H, Costa JA, Lopez P, Davidowitz E, Yu WH, Haroutunian V, Brown LM, Palmeri A, Sigurdsson EM, Duff KE, Teich AF, Honig LS, Sierks M, Moe JG, D'Adamio L, Grassi C, Kanaan NM, Fraser PE, Arancio O.

Sci Rep. 2016 Jan 20;6:19393. doi: 10.1038/srep19393.

Supplemental Content

Support Center